While Illumina (ILMN +3.9%) has rebounded from the weakness caused by Life Technologies' (LIFE +7.2%) product announcement, smaller rival Complete Genomics' (GNOM -19.9%) bloodletting worsens as the day progresses. On Monday, the company announced it delivered 300 fewer genomes in Q4 than previously expected, news that triggered a downgrade from Oppenheimer.
While Illumina (ILMN +3.9%) has rebounded from the weakness caused by Life Technologies' (LIFE...
From other sites
Video at CNBC.com (Jun 28, 2016)
Video at CNBC.com (Apr 19, 2016)
Video at CNBC.com (Oct 6, 2015)
at CNBC.com (Jan 9, 2015)
at CNBC.com (Dec 29, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs